Though the association between overactive bladder (OAB) and depression was noticed years ago, the pharmaceutical market does not offer one universal drug that would cure both conditions at the same time. The main goal of our present experiments was to determine whether a 14-day administration of solifenacin (0.03 mg/kg/day), mirabegron (1 mg/kg/day), or duloxetine (1 mg/kg/day) would reverse detrusor overactivity and depression-like signs in female Wistar rats subjected to corticosterone treatment. Surgical procedures, cystometric studies, biochemical analyses, and the forced swim test were performed according to published literature. After 14 days of exposure to corticosterone (20 mg/kg/day, subcutaneously), the tested animals presented symptoms of depression, detrusor overactivity, inflammation, and disturbances in neurotrophic factors. The obtained results demonstrated that solifenacin and mirabegron act mainly via peripheral pathways in OAB, whereas the central pathways are responsible for the effects of duloxetine. 72 h after discontinuation of duloxetine treatment, positive changes in the corticosterone-induced depression, detrusor overactivity, and inflammation were observed. Duloxetine seems to have a potential to become a new treatment option for patients with OAB co-existing with depression.

尽管几年前就注意到膀胱过度活动症（OAB）与抑郁症之间的关联，但制药市场并未提供一种可以同时治愈两种疾病的通用药物。我们目前实验的主要目标是确定服用14天的索非那新（0.03 mg / kg /天），米拉贝隆（1 mg / kg /天）或度洛西汀（1 mg / kg /天）是否会逆转逼尿肌。雌性Wistar大鼠接受皮质酮治疗后会出现过度活动和抑郁样症状。根据已发表的文献进行了外科手术，膀胱测压研究，生化分析和强迫游泳试验。在暴露于皮质酮14天后（皮下注射20 mg / kg /天），被测动物表现出抑郁，逼尿肌过度活动，炎症和神经营养因子紊乱的症状。获得的结果表明，索非那新和米拉贝隆主要通过OAB中的外周途径起作用，而中枢途径负责度洛西汀的作用。停用度洛西汀治疗72小时后，观察到皮质酮诱导的抑郁，逼尿肌过度活动和炎症发生了积极变化。对于患有OAB并存抑郁症的患者，度洛西汀似乎有可能成为一种新的治疗选择。